Janus Henderson Group
TRVI icon

Janus Henderson Group’s Trevi Therapeutics TRVI Stock Holding History

Janus Henderson Group’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$443K Hold
37,127
– – ﹤0.01% 2062
2025
Q4 		$464K Hold
37,127
– – ﹤0.01% 2040
2025
Q3 		$340K Buy
+37,127
New +$278K ﹤0.01% 2157

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Janus Henderson Group's TRVI Position: Q1 2026 in Review

Janus Henderson Group held its Trevi Therapeutics (TRVI) position steady in Q1 2026 at 37,127 shares worth $443K. The position accounts for ﹤0.01% of the portfolio, ranked #2062.

Janus Henderson Group first reported a position in TRVI in Q3 2025 and has held it in 3 quarters since. The position peaked at $464K in Q4 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Janus Henderson Group held 37,127 shares of Trevi Therapeutics worth $443K as of Q1 2026.
  • Janus Henderson Group left its Trevi Therapeutics share count unchanged in Q1 2026.
  • Trevi Therapeutics made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #2062 holding.
  • Janus Henderson Group first reported a position in Trevi Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Janus Henderson Group's Trevi Therapeutics position peaked at $464K in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.